.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

Global Oncology News
AML: Evolving Perspectives on Testing, Therapies, & Transplantation
Join us to learn about the impact of MRD in cancer

SpecialtySee All >

Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma

Advertise
About OncLive
Editorial Board
CureToday.com
TargetedOnc.com
CancerNetwork.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Refining Treatment Approaches for HER2+ Breast Cancer

HR-/HER2+ Early Stage Breast Cancer: Standards of Care

January 20th 2021

Adjuvant Systemic Therapy Decision Factors

January 20th 2021

Adjuvant Systemic Therapy Data Updates

January 29th 2021

De-Escalation of Adjuvant Anti-HER2 Therapy and Chemo

January 29th 2021

Hormone Therapy in HER2+ Breast Cancer

February 5th 2021

Moving Metastatic Therapy to Early Stage Setting

February 5th 2021

Newly FDA Approved Therapies: R/R HER2+ MBC

February 12th 2021

Sequencing Therapy in R/R HER2+ MBC

February 12th 2021

Brain Metastases Therapy in Second-Line HER2+ MBC

February 19th 2021

Practical Advice for Toxicity Management in HER2+ MBC

February 19th 2021